| Residential College | false |
| Status | 已發表Published |
| Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs | |
Tam, K. Y.
| |
| 2013-09-01 | |
| Source Publication | ADMET & DMPK
 |
| ISSN | 1848-7718 |
| Pages | 63-75 |
| Abstract | The initial dose selection is one of the important steps for any investigative new drug (IND) entering the first clinical study in humans. In this mini review, we will discuss the no observed adverse effect level (NOAEL) and the minimum anticipated biological effect level (MABEL) approaches for the estimation of the first in human (FIH) dose. Particular attention will be placed on the development of the FIH dose for oncology drugs. |
| Keyword | Initial Dose Starting Dose Clinical Trial Noael Mabel Cytotoxic Anticancer Combination Therapy Study |
| DOI | 10.5599/admet.1.4.10 |
| Language | 英語English |
| The Source to Article | PB_Publication |
| Fulltext Access | |
| Citation statistics | |
| Document Type | Journal article |
| Collection | DEPARTMENT OF PHARMACEUTICAL SCIENCES Faculty of Health Sciences |
| Recommended Citation GB/T 7714 | Tam, K. Y.. Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs[J]. ADMET & DMPK, 2013, 63-75. |
| APA | Tam, K. Y..(2013). Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs. ADMET & DMPK, 63-75. |
| MLA | Tam, K. Y.."Estimating the “First in human” dose – a revisit with particular emphases in oncology drugs".ADMET & DMPK (2013):63-75. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment